Shows & Panels
- Accelerate and Streamline for Better Customer Service
- Ask the CIO
- The Big Data Dilemma
- Carrying On with Continuity of Operations
- Client Virtualization Solutions
- Data Protection in a Virtual World
- Expert Voices
- Federal Executive Forum
- Federal IT Challenge
- Federal Tech Talk
- Feds in the Cloud
- Health IT: A Policy Change Agent
- IT Innovation in the New Era of Government
- Making Dollars And Sense Out of Data Center Consolidation
- Navigating the Private Cloud
- One Step to the Cloud, Two Steps Toward Innovation
- Path to FDCCI Compliance
- Take Command of Your Mobility Initiative
Shows & Panels
New NIH center translates research into real-world use
Friday - 1/13/2012, 11:07am EST
The reorganization was the biggest at NIH in a decade, according to ScienceInsider Magazine.
Dr. Thomas Insel, acting director, NCATS (photo from NIH.gov)
NCATS will focus not so much on curing diseases but on examining the process of finding cures, Insel said.
"All of us — the 27 institutes and centers at NIH — are involved in translation in various ways. But none of us do the kinds of work to actually improve the process of translation. That's what NCATS can do," he said.
One area the center is focused on is autism, which the medical field has traditionally treated through behavioral interventions, even though autism is a developmental brain disease, Insel said.
"What this new entity could do is to begin to identify the molecular targets that will be important to the disease process itself and help us to find how to go and treat those targets in such a way so we treat autism the way we treat many other biomedical problems," Insel said.
The establishment of NCATS reinforces a "much more workable partnership" between NIH and the Food and Drug Administration, as well as the Defense Advanced Research Projects Agency. The three agencies are working on a project to develop chip technology that can allow researchers to more effectively screen drugs.
The center was created as part of the fiscal 2012 spending bill, receiving a budget of $575 million. But NCATS does not rely on any new money and instead is a rejiggering of the current NIH structure — mainly from programs previously located in the NIH Office of the Director, National Human Genome Research Institute, and National Center for Research Resources.
Insel said the center thinks of itself as an investment. There are 6,000 rare or neglected diseases, but treatments for only 225 of them, he said. The goal of translating science to real-world use is not a five-to-10-year process, Insel said.
"The way we think about our mission is we're in it to win it," he said.